MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2019.106263

Медицинская библиотека · Leukemia research · 2019

Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.

Miyamura Takako, Kudo Kazuko, Tabuchi Ken, Ishida Hiroyuki, Tomizawa Daisuke, Adachi Souichi, Goto Hiroaki, Yoshida Nao, Inoue Masami, Koh Katsuyoshi, Sasahara Yoji, Fujita Naoto, Kakuda Harumi, Noguchi Maiko, Hiwatari Mitsuteru, Hashii Yoshiko, Kato Koji, Atsuta Yoshiko, Okamoto Yasuhiro

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

Pediatric acute myeloid leukemia (AML) with KMT2A rearrangement is detected in 15-20% of all pediatric AML patients and is associated with adverse outcomes even after allogeneic hematopoietic stem cell transplantation (HSCT). To investigate outcomes and prognostic factors, we investigated 90 pediatric AML patients with KMT2A rearrangement after allogeneic HSCT.

METHODS

We retrospectively analyzed Japanese registration data for patients who had received allogeneic HSCT between 1988 and 2011. Median age was 3 years (range, 0-15 years), and no gender difference was evident. Median observation period was 119 months.

RESULTS

The 3-year overall survival (OS) rate of KMT2A-rearranged AML was 52.1% (95% confidence interval (CI), 42.4-64%, n = 90), and the 3-year disease-free survival (DFS) rate was 46.7% (95%CI, 36.8-58.2%). The 3-year DFS of KMT2A-rearranged AML was not significantly poorer than that of other AML (P = 0.09), and no significant difference was also seen in 3-year OS rate (P = 0.21). Multivariate analysis showed disease status (complete remission) at HSCT was associated with better outcomes. A significant difference in treatment-related mortality (TRM) was apparent between HSCT from a HLA full-matched related donor and that from a haploidentical donor (P = 0.001).

DISCUSSION: HSCT is a curative option for pediatric AML with KMT2A rearrangement. Pretransplant status was the most significant prognostic indicator for relapse and survival. Enhancing supportive therapy to reduce TRM will further improve treatment outcomes of KMT2A-rearranged pediatric AML.

Для цитирования: Miyamura Takako, Kudo Kazuko, Tabuchi Ken, Ishida Hiroyuki, Tomizawa Daisuke, Adachi Souichi, Goto Hiroaki, Yoshida Nao, Inoue Masami, Koh Katsuyoshi, Sasahara Yoji, Fujita Naoto, Kakuda Harumi, Noguchi Maiko, Hiwatari Mitsuteru, Hashii Yoshiko, Kato Koji, Atsuta Yoshiko, Okamoto Yasuhiro. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.. Leukemia research. 2019. DOI: 10.1016/j.leukres.2019.106263.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.